Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele

Chronic myeloid leukemia in chronic phase (CML-CP) cells that harbor oncogenic BCR-ABL1 and normal ABL1 allele often become resistant to the ABL1 kinase inhibitor imatinib. Here we report that loss of the remaining normal ABL1 allele in these tumors, which results from cryptic interstitial deletion...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Virgili, Anna, Koptyra, Mateusz, Dasgupta, Yashodhara, Glodkowska-Mrowka, Eliza, Stoklosa, Tomasz, Nacheva, Elisabeth P., Skorski, Tomasz
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3156347/
https://ncbi.nlm.nih.gov/pubmed/21693657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-0068
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky